References
- Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011; 23:286-92; PMID: 21185705; http://dx.doi.org/10.1016/j.coi.2010.11.013
- Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 2012; 13:1105-13; PMID: 23059047; http://dx.doi.org/10.1016/S1470-2045(12)70263-2
- Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, et al. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clin Cancer Res Off J Am Asso Cancer Res 2014; 20(12):3310-18
- Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2013; 31:616-22; PMID: 23295794; http://dx.doi.org/10.1200/JCO.2012.44.6112
- Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res Official J Am Asso Cancer Res 2010; 16:1042-8; PMID: 20086001; http://dx.doi.org/10.1158/1078-0432.CCR-09-2033
- Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res official J Am Assoc Cancer Res 2013; 19:1009-20; PMID: 23460532; http://dx.doi.org/10.1158/1078-0432.CCR-12-2982
- Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. Sci Trans Med 2014; 6:238ra70; http://dx.doi.org/10.1126/scitranslmed.3008211
- Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immun: CII 2012; 61:1019-31; PMID: 22146893; http://dx.doi.org/10.1007/s00262-011-1172-6
- Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas K, Cortez C, Rasalan T, Adamow M, Yuan J, Wong P, et al. Computational Algorithm Driven Evaluation of Monocytic Myeloid Derived Suppressor Cell Frequency For Prediction of Clinical Outcomes. Cancer Immunol Res 2014; 2(8):1-10.
- Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2:127-32; PMID: 24778276; http://dx.doi.org/10.1158/2326-6066.CIR-13-0163